NCT00443677已完成3 期
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)
Gruppo Italiano Studio Linfomi1 个研究点 分布在 1 个国家目标入组 307 人开始时间: 2000年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 307
- 试验地点
- 1
- 主要终点
- To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens
研究概览
简要总结
The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of Hodgkin disease
- •Clinical stage IIB, III, IV
- •No prior treatment for Hodgkin disease or other malignancy
- •Age 18-65 year
- •Good cardiac, pulmunar, renal and hepatic function
- •Performance status 0-3 (Karnofsky 100- 40)
- •Written Informed Consent
排除标准
- •HIV positivity
- •Large cell, anaplastic, CD30+ lymphoma
研究组 & 干预措施
abvd
Active Comparator
干预措施: COPPEBVCAD vs BEACOPP vs ABVD (Drug)
beacopp
Experimental
干预措施: COPPEBVCAD vs BEACOPP vs ABVD (Drug)
coppebvcad
Experimental
干预措施: COPPEBVCAD vs BEACOPP vs ABVD (Drug)
结局指标
主要结局
To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens
次要结局
- To compare the results in terms of response, failure free survival and relapse free survival of the three regimens
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
HD11 for Intermediate StagesHodgkin´s LymphomaNCT00264953University of Cologne1,395
已完成
不适用
Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve OutcomesHodgkin's LymphomaNCT01304849Cancer Institute WIA50
已完成
2 期
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 YearsLymphomaNCT00079105Newcastle-upon-Tyne Hospitals NHS Trust175
已完成
不适用
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaHodgkin Lymphoma, AdultNCT01578967UNC Lineberger Comprehensive Cancer Center41
已完成
2 期
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's LymphomaHodgkin DiseaseNCT01195766Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea64